Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers von Peng, Sheng-Bin, Henry, James R., Kaufman, Michael D., Lu, Wei-Ping, Smith, Bryan D., Vogeti, Subha, Rutkoski, Thomas J., Wise, Scott, Chun, Lawrence, Zhang, Youyan, Van Horn, Robert D., Yin, Tinggui, Zhang, Xiaoyi, Yadav, Vipin, Chen, Shih-Hsun, Gong, Xueqian, Ma, Xiwen, Webster, Yue, Buchanan, Sean, Mochalkin, Igor, Huber, Lysiane, Kays, Lisa, Donoho, Gregory P., Walgren, Jennie, McCann, Denis, Patel, Phenil, Conti, Ilaria, Plowman, Gregory D., Starling, James J., Flynn, Daniel L.

Volltext

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants von Smith, Bryan D., Kaufman, Michael D., Lu, Wei-Ping, Gupta, Anu, Leary, Cynthia B., Wise, Scott C., Rutkoski, Thomas J., Ahn, Yu Mi, Al-Ani, Gada, Bulfer, Stacie L., Caldwell, Timothy M., Chun, Lawrence, Ensinger, Carol L., Hood, Molly M., McKinley, Arin, Patt, William C., Ruiz-Soto, Rodrigo, Su, Ying, Telikepalli, Hanumaiah, Town, Ajia, Turner, Benjamin A., Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen, Janku, Filip, Abdul Razak, Albiruni Ryan, Rosen, Oliver, Heinrich, Michael C., Flynn, Daniel L.

Volltext

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036 von Chan, Wayne W., Wise, Scott C., Kaufman, Michael D., Ahn, Yu Mi, Ensinger, Carol L., Haack, Torsten, Hood, Molly M., Jones, Jennifer, Lord, John W., Lu, Wei Ping, Miller, David, Patt, William C., Smith, Bryan D., Petillo, Peter A., Rutkoski, Thomas J., Telikepalli, Hanumaiah, Vogeti, Lakshminarayana, Yao, Tony, Chun, Lawrence, Clark, Robin, Evangelista, Peter, Gavrilescu, L. Cristina, Lazarides, Katherine, Zaleskas, Virginia M., Stewart, Lance J., Van Etten, Richard A., Flynn, Daniel L.

Volltext

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models von Piao, Yuji, Park, Soon Young, Henry, Verlene, Smith, Bryan D, Tiao, Ningyi, Flynn, Daniel L, de Groot, John F

Volltext

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy von Yu, Yasmin, Bogdan, Madhumita, Noman, Muhammad Zaeem, Parpal, Santiago, Bartolini, Elisabetta, Van Moer, Kris, Kleinendorst, Simone Caroline, Bilgrav Saether, Kristine, Trésaugues, Lionel, Silvander, Camilla, Lindström, Johan, Simeon, Jodi, Timson, Mary Jane, Al‐Hashimi, Hikmat, Smith, Bryan D., Flynn, Daniel L., Alexeyenko, Andrey, Viklund, Jenny, Andersson, Martin, Martinsson, Jessica, Pokrovskaja Tamm, Katja, De Milito, Angelo, Janji, Bassam

Volltext

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia von Cortes, Jorge, Talpaz, Moshe, Smith, Hedy P, Snyder, David S, Khoury, Jean, Bhalla, Kapil N, Pinilla-Ibarz, Javier, Larson, Richard, Mitchell, David, Wise, Scott C, Rutkoski, Thomas J, Smith, Bryan D, Flynn, Daniel L, Kantarjian, Hagop M, Rosen, Oliver, Van Etten, Richard A

Volltext

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors von Harney, Allison S., Karagiannis, George S., Pignatelli, Jeanine, Smith, Bryan D., Kadioglu, Ece, Wise, Scott C., Hood, Molly M., Kaufman, Michael D., Leary, Cynthia B., Lu, Wei-Ping, Al-Ani, Gada, Chen, Xiaoming, Entenberg, David, Oktay, Maja H., Wang, Yarong, Chun, Lawrence, De Palma, Michele, Jones, Joan G., Flynn, Daniel L., Condeelis, John S.

Volltext

Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis von Gupta, Anu, Singh, Jarnail, Garcia-Valverde, Alfonso, Serrano, Cesar, Flynn, Daniel L., Smith, Bryan D.

Volltext

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages von Smith, Bryan D., Kaufman, Michael D., Wise, Scott C., Ahn, Yu Mi, Caldwell, Timothy M., Leary, Cynthia B., Lu, Wei-Ping, Tan, Gege, Vogeti, Lakshminarayana, Vogeti, Subha, Wilky, Breelyn A., Davis, Lara E., Sharma, Maitreyi, Ruiz-Soto, Rodrigo, Flynn, Daniel L.

Volltext

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT) von Caldwell, Timothy M., Ahn, Yu Mi, Bulfer, Stacie L., Leary, Cynthia B., Hood, Molly M., Lu, Wei-Ping, Vogeti, Lakshminarayana, Vogeti, Subha, Kaufman, Michael D., Wise, Scott C., Le Bourdonnec, Bertrand, Smith, Bryan D., Flynn, Daniel L.

Volltext

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors von Caldwell, Timothy M., Kaufman, Michael D., Wise, Scott C., Mi Ahn, Yu, Hood, Molly M., Lu, Wei-Ping, Patt, William C., Samarakoon, Thiwanka, Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen M., Bulfer, Stacie L., Le Bourdonnec, Bertrand, Smith, Bryan D., Flynn, Daniel L.

Volltext

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)­pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxi... von Henry, James R, Kaufman, Michael D, Peng, Sheng-Bin, Ahn, Yu Mi, Caldwell, Timothy M, Vogeti, Lakshminarayana, Telikepalli, Hanumaiah, Lu, Wei-Ping, Hood, Molly M, Rutkoski, Thomas J, Smith, Bryan D, Vogeti, Subha, Miller, David, Wise, Scott C, Chun, Lawrence, Zhang, Xiaoyi, Zhang, Youyan, Kays, Lisa, Hipskind, Philip A, Wrobleski, Aaron D, Lobb, Karen L, Clay, Julia M, Cohen, Jeffrey D, Walgren, Jennie L, McCann, Denis, Patel, Phenil, Clawson, David K, Guo, Sherry, Manglicmot, Danalyn, Groshong, Chris, Logan, Cheyenne, Starling, James J, Flynn, Daniel L

Volltext

Potent Inhibition of Ribonuclease A by Oligo(vinylsulfonic Acid) von Smith, Bryan D., Soellner, Matthew B., Raines, Ronald T.

Volltext

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2 von Smith, Bryan D, Kaufman, Michael D, Leary, Cynthia B, Turner, Benjamin A, Wise, Scott C, Ahn, Yu Mi, Booth, R John, Caldwell, Timothy M, Ensinger, Carol L, Hood, Molly M, Lu, Wei-Ping, Patt, Tristan W, Patt, William C, Rutkoski, Thomas J, Samarakoon, Thiwanka, Telikepalli, Hanumaiah, Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen M, Chun, Lawrence, Stewart, Lance J, Clare, Michael, Flynn, Daniel L

Volltext

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer von Ghazi, Phaedra C, O'Toole, Kayla T, Srinivas Boggaram, Sanjana, Scherzer, Michael T, Silvis, Mark R, Zhang, Yun, Bogdan, Madhumita, Smith, Bryan D, Lozano, Guillermina, Flynn, Daniel L, Snyder, Eric L, Kinsey, Conan G, McMahon, Martin

Volltext

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile von Eide, Christopher A, Adrian, Lauren T, Tyner, Jeffrey W, Mac Partlin, Mary, Anderson, David J, Wise, Scott C, Smith, Bryan D, Petillo, Peter A, Flynn, Daniel L, Deininger, Michael W N, O'Hare, Thomas, Druker, Brian J

Volltext

Abstract 4889: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models von Smith, Bryan D., Leary, Cynthia B., Lu, Wei-Ping, Kaufman, Michael D., Flynn, Daniel L.

Volltext

Functional and structural analyses of N-acylsulfonamide-linked dinucleoside inhibitors of RNase A von Thiyagarajan, Nethaji, Smith, Bryan D, Raines, Ronald T, Acharya, K. Ravi

Volltext

Biomimetic Synthesis of the Putative Cytotoxin Peroxynitrite, ONOO-, and Its Characterization as a Tetramethylammonium Salt von Bohle, D. Scott, Hansert, Bernhard, Paulson, Scott C, Smith, Bryan D

Volltext

Site-specific folate conjugation to a cytotoxic protein von Smith, Bryan D., Higgin, Joshua J., Raines, Ronald T.

Volltext